gebhart/patrepeval huggingface dataset:
Simple, Efficient and Effective Encodings of Local Deep Features for Video Action Recognition (2017)

For an action recognition system a decisive component is represented by the feature encoding part which builds the final representation that serves as input to a classifier. One of the shortcomings of the existing encoding approaches is the fact that they are built around hand-crafted features and they are not also highly competitive on encoding the current deep features, necessary in many practical scenarios. In this work we propose two solutions specifically designed for encoding local deep features, taking advantage of the nature of deep networks, focusing on capturing the highest feature response of the convolutional maps. The proposed approaches for deep feature encoding provide a solution to encapsulate the features extracted with a convolutional neural network over the entire video. In terms of accuracy our encodings outperform by a large margin the current most widely used and powerful encoding approaches, while being extremely efficient for the computational cost. Evaluated in the context of action recognition tasks, our pipeline obtains state-of-the-art results on three challenging datasets: HMDB51, UCF50 and UCF101.
Re-Configurable Wavelength De-Multiplexer in Wavelength Division Multiplexed Radio-over-Fiber Systems for Frequency-Modulated Continuous-Wave Signal Delivery (2015)

A re-configurable wavelength de-multiplexer for wave-length-division-multiplexed (WDM) radio-over-fiber (RoF) systems, which is specially designed for delivering frequency-modulated continuous-wave (FM-CW) signals, is newly developed. The principle and characteristics of the developed de-multiplexer are described in detail. Then the de-multiplexing performances of 4-channel WDM 32-GHz-band, 8-channel WDM 48-GHz-band, and 5-channel WDM 96-GHz-band FM-CW RoF signals are evaluated with the de-multiplexer.
Pentacyanoferrate(II) complexes of amino acids (1982)

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTPentacyanoferrate(II) complexes of amino acidsHenrique Toma, Alzir A. Batista, and Harry B. GrayCite this: J. Am. Chem. Soc. 1982, 104, 26, 7509–7515Publication Date (Print):December 1, 1982Publication History Published online1 May 2002Published inissue 1 December 1982https://pubs.acs.org/doi/10.1021/ja00390a020https://doi.org/10.1021/ja00390a020research-articleACS PublicationsRequest reuse permissionsArticle Views373Altmetric-Citations63LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose Get e-Alerts
Abstract 449: Targeted proteomic analysis for personalized treatment of muscle invasive bladder cancer (2016)

Abstract Background: Standard treatment for muscle-invasive bladder cancer (MIBC) includes chemotherapy with either gemcitabine-cisplatin (GC) or methotrexate, vinblastine, adriamycin and cisplatin (MVAC). These regimens have similar clinical complete response rates of approximately 30%. While no targeted treatment has been approved for bladder cancer, clinical trials have identified biochemical markers that predict the chemoresponsiveness of MIBC tumors to specific chemotherapeutic agents. For example, patients with high hENT1 and low RRM1 expression responded better to GC-based chemotherapy than their counterparts, and HER2 overexpression predicted resistance to cisplatin-based therapy. To quantify targets that are known indicators of tumor behavior, we used targeted proteomic analysis to assess 30 different protein biomarkers in formalin-fixed paraffin-embedded (FFPE) MIBC tumor tissue. Methods: Twelve FFPE MIBC tissue blocks were obtained and a pathologist marked a minimum 8mm2 of tumor area from 1 or 2 slides. Following laser microdissection of the marked areas, proteins were extracted using the Liquid-Tissue® process and subjected to selected reaction monitoring mass spectrometry to quantify the amounts of 30 different targeted proteins in each patient sample. Results: Of the 12 patient samples, 7 (58%) expressed high levels of hENT1 and 11 (92%) expressed low levels of RRM1, indicating that gemcitabine-based therapy would be an appropriate choice. A single patient expressed high levels of RRM1, an indication for non-gemcitabine based therapy. All 12 patients expressed TUBB3, a marker of resistance to taxane (vinblastine) and 10 patients (83%) lacked expression of FR-alpha, a marker of sensitivity to methotrexate. The majority of patients expressed a marker of sensitivity to anthracycline (TOPO2A) and did not express a resistance biomarker for platinum therapy (ERCC1). Of 3 patients whose tumors expressed HER2, 2 had overexpression (&amp;gt;750 amol/ug) and would thus be eligible for HER2 basket trials. Further, multiplex-targeted proteomics discovered patients expressing FGFR1 (17%), cMET (33%), Axl (17%) and IDO1 (25%), which would make them eligible for clinical trials of targeted or immunotherapies. Conclusion: MIBC is heterogeneous and expresses a wide range of proteins. Yet, it continues to be treated with only 2 chemotherapeutic regimens. Multiplexed proteomics is currently being used in clinical practice to inform personalized patient care decisions with identification and the relative quantities of actionable proteins known to predict tumor behavior. Citation Format: Fabiola Cecchi, Sheeno Thyparambil, Adele Blackler, Todd Hembrough, Shahrooz Rabizadeh, Patrick Soon-Shiong, Henry Frierson, Daniel Theodorescu. Targeted proteomic analysis for personalized treatment of muscle invasive bladder cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 449.
Abstract 960: Ceramide-dependent release of nanovesicles is a class effect oflipid-based Akt inhibitors (2011)

Abstract Akt regulates many cellular processes and Akt inhibitors are being developed as cancer therapeutics. The mechanism of action of lipid-based Akt inhibitors (LBAIs) such as perifosine and phosphatidylinositol ether lipid analogues (PIAs) is incompletely understood. Here, we show that LBAIs quickly deplete cells of proteins such as EGFR, IGFR and p-Akt that can be recovered in tetraspanin-enriched 100,000 xg pellets from conditioned media. Electron micrographs of these pellets exhibited heterogenous vesicular structures whose diameter was less than 1 µM. In vitro, LBAI treatment increased vesicle shedding as revealed by live cell microscopy. In vivo, LBAIs increased plasma levels of nanovesicles derived from tumor xenografts. Several lines of evidence show that release of nanovesicles by LBAI depends upon ceramide generation. LBAIs increased levels of cellular ceramide, and addition of exogenous ceramide stimulated nanovesicle release. GW4869, an inhibitor of sphingomyelinase, an enzyme that generates ceramide by cleavage of sphingomyelin, blocked release of nanovesicles induced by LBAI. When transferred in vitro, purified nanovesicles increased ceramide levels and inhibited proliferation of naïve recipient cells, suggesting these contain residual LBAIs. Pre-treatment with GW4869 blocked ceramide induction in recipient cells and yielded greater retention of the donor nanovesicles. These studies identify ceramide-dependent release of cellular nanovesicles as a class effect of LBAI and a novel means to shed EGFR, IGF-IR and p-Akt from tumors that could perpetuate the cytotoxicity of LBAIs. We believe this is the first report of secondary pharmacologic effects via cell-mediated drug transfer in nanovesicles. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 960. doi:10.1158/1538-7445.AM2011-960
TableS5 from Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma (2023)

&lt;p&gt;Supplementary table 5&lt;/p&gt;
The B29 (Immunoglobulin β-Chain) Gene Is a Genetic Target for Early B-Cell Factor (1999)

Early B-cell factor (EBF) is a transcription factor suggested as essential for early B-lymphocyte development by findings in mice where the coding gene has been inactivated by homologous disruption. This makes the identification of genetic targets for this transcription factor pertinent for the understanding of early B-cell development. The lack of B29 transcripts, coding for the beta subunit of the B-cell receptor complex, in pro-B cells from EBF-deficient mice suggested that B29 might be a genetic target for EBF. We here present data suggesting that EBF interacts with three independent sites within the mouse B29 promoter. Furthermore, ectopic expression of EBF in HeLa cells activated a B29 promoter-controlled reporter construct 13-fold and induced a low level of expression from the endogenous B29 gene. Finally, mutations in the EBF binding sites diminished B29 promoter activity in pre-B cells while the same mutations did not have as striking an effect on the promoter function in B-cell lines of later differentiation stages. These data suggest that the B29 gene is a genetic target for EBF in early B-cell development.
ALD-based confined PCM with a metallic liner toward unlimited endurance (2016)

We present for the first time in-depth analysis of the outstanding endurance characteristics of an ALD-based confined phase change memory (PCM) [1] with a thin metallic liner. Experimental results confirm that both the proper metallic liner and the confined pore cell structure are required for a reliability advantage. This confined PCM with a metallic liner is found to be immune to classic endurance failure mechanisms. The void-free confined PCM yields a new record endurance (2×10 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">12</sup> cycles) with stabilized elemental segregation that does not result in stuck-SET failure.
A Different Angle on Light Communications (2012)

Can “twisted” light beams enhance optical communication systems?
Effects of Annealing and Atomic Hydrogen Treatment on Aluminum Oxide Passivation Layers for Crystalline Silicon Solar Cells (2011)

The effects of annealing and atomic hydrogen treatment (AHT) on the interface between hydrogenated aluminum oxide (a-Al 1- x O x :H) and crystalline silicon (c-Si) were investigated. The annealing increased the negative interface fixed charge density ( Q f ) from -4.0×10 11 to -3.0×10 12 cm -2 , whereas AHT reduced Q f from -3.0×10 12 to 8.3×10 11 cm -2 . Chemical composition analyses revealed the existence of a hydrogenated silicon oxide (a-Si 1- x O x :H) interfacial layer. It was also found that annealing and AHT strongly affected the chemical compositions near the interfacial layer. The change in Q f is probably caused by the reaction at the interface between the a-Al 1- x O x :H and a-Si 1- x O x :H.
Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection (2015)

The Staphylococcus aureus virulence factor clumping factor A (ClfA) is a component of an investigational S. aureus prophylactic vaccine. ClfA enables S. aureus to bind to fibrinogen and platelets during the initial stages of invasive disease. Here we demonstrate that ectopic expression of ClfA is sufficient to render nonpathogenic Lactococcus lactis lethal in a murine model of systemic infection. In contrast, L. lactis expressing ClfAY338A, which cannot bind fibrinogen, did not cause death in the mice. Pathogenicity was also prevented by immunization with ClfA. This model was then used to define a preclinical correlate of protection by measuring functional antibody in a S. aureus fibrinogen binding inhibition assay (FBI) and correlating that titer with protective outcomes. Although many humans have pre-existing antibodies that bind to ClfA, only sera with a threshold functional titer in the FBI were protective in this preclinical model. This confirms that fibrinogen binding is critical for ClfA-mediated pathogenesis and demonstrates that functional antibodies against ClfA are sufficient to protect against ClfA-mediated pathogenesis in vivo, enabling the definition of a preclinical correlate of protection for ClfA-containing vaccines based on FBI titer.
Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence (2020)

Plasma assay of novel colorectal cancer-associated MDMs can reliably detect both primary colorectal cancer and distantly recurrent colorectal cancer with promising accuracy.
Steady-state first-pass perfusion (SSFPP): A 3D TWIST in myocardial first-pass perfusion imaging (2012)

A new approach to myocardial first-pass perfusion imaging is presented; this technique, called SSFPP, is based on 3D SSFP sequence whereby magnetization is maintained in constant steady-state, while data acquisition is gated to diastole. This results in high SNR and CNR, and other characteristics that can potentially mitigate dark rim artifacts. The high-blood myocardial contrast of SSFP allows automatic segmentation, which, combined with registration, facilitates image analysis.
Atherosclerotic Peripheral Vascular Disease Symposium II (2008)

Percutaneous intervention for peripheral artery disease hasevolved from balloon angioplasty for simple focal lesions to multimodality techniques that enable treatment of severe arterial insufficiency. This technological expansion comes without a standard approach or algorithm, which makes the decision-making process more subjective than objective. Nevertheless, clinical tools are available that can have a favorable effect on patient care, and these promote usage. So, when are standard endovascular techniques (such as balloon and stents) good enough, and when are the latest advances (eg, atherectomy, drug-eluting stents) more appropriate? This section will address these questions for acute limb ischemia (ALI) and chronic critical limb ischemia (CLI). It will also delineate the problem of restenosis, particularly of the superficial femoral artery (SFA), and describe treatment alternatives. The discussion will review the role of drug-
Radiation-guided drug delivery systems (2004)

A primary limiting factor for cancer treatment is normal tissue toxicity. Targeted cancer treatment can potentially maximize cancer cure and minimize normal tissue toxicity. Physical energy can be used to activate inert oncologic drugs. X-rays have an advantage over other forms of physical energy because tissue penetration and precise localization can be achieved. Radiation can be used to control drug delivery through radiation-inducible gene therapy. Radiation-guided drug delivery systems involve the targeting of immunoconjugates to radiation-inducible neoantigens induced by irradiation of neoplasms. Magnetic fields can compliment these technologies by drawing magnetic particles containing oncologic drugs toward an externally applied magnetic field. The field of targeted drug delivery by use of external radiation fields will ultimately bring new delivery systems into clinical trials. This review highlights radiation-guided cancer drug delivery systems, at preclinical and clinical stages of development, to tumors and tumor blood vessels.
Age effects upon the harmonic structure of human blood pressure in clinical health (2003)

Ambulatory blood pressure monitoring of 180 clinically healthy adults of both genders is used to investigate and compare ultradian aspects of systolic and diastolic blood pressure as a function of age. Three age categories are considered: 20-40, 40-60, and over 60 years of age. results from least-squares spectra of each data series are further examined by analysis of variance. Gender and age effects are found to characterize the waveform of human blood pressure. These effects can be quantified by spectral analysis and may represent gauges of aging.< <ETX xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&gt;</ETX>
High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers (2018)

THIOMAB antibody technology utilizes cysteine residues engineered onto an antibody to allow for site-specific conjugation. The technology has enabled the exploration of different attachment sites on the antibody in combination with small molecules, peptides, or proteins to yield antibody conjugates with unique properties. As reported previously ( Shen , B. Q. , et al. ( 2012 ) Nat. Biotechnol. 30 , 184 - 189 ; Pillow , T. H. , et al. ( 2017 ) Chem. Sci. 8 , 366 - 370 ), the specific location of the site of conjugation on an antibody can impact the stability of the linkage to the engineered cysteine for both thio-succinimide and disulfide bonds. High stability of the linkage is usually desired to maximize the delivery of the cargo to the intended target. In the current study, cysteines were individually substituted into every position of the anti-HER2 antibody (trastuzumab), and the stabilities of drug conjugations at those sites were evaluated. We screened a total of 648 THIOMAB antibody-drug conjugates, each generated from a trastuzamab prepared by sequentially mutating non-cysteine amino acids in the light and heavy chains to cysteine. Each THIOMAB antibody variant was conjugated to either maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethyl auristatin E (MC-vc-PAB-MMAE) or pyridyl disulfide monomethyl auristatin E (PDS-MMAE) using a high-throughput, on-bead conjugation and purification method. Greater than 50% of the THIOMAB antibody variants were successfully conjugated to both MMAE derivatives with a drug to antibody ratio (DAR) of >0.5 and <50% aggregation. The relative in vitro plasma stabilities for approximately 750 conjugates were assessed using enzyme-linked immunosorbent assays, and stable sites were confirmed with affinity-capture LC/MS-based detection methods. Highly stable conjugation sites for the two types of MMAE derivatives were identified on both the heavy and light chains. Although the stabilities of maleimide conjugates were shown to be greater than those of the disulfide conjugates, many sites were identified that were stable for both. Furthermore, in vitro stabilities of selected stable sites translated across different cytotoxic payloads and different target antibodies as well as to in vivo stability.
A 1856 I/O cell CMOS SOG with half-ns clock skew and a 6 ns RAM (2003)

A 177 K CMOS sea-gates has been developed by applying a 0.8- mu m triple-metal-layer process technology. Its speed reaches 200 ps, and 120 K usable gates can be provided. A high-speed RAM (6 ns typical access time) of high-density type (64 kbit maximum) can be implemented on it. It has 1856 I/O cells which offer much flexibility in the construction of I/O buffers.< <ETX xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&gt;</ETX>
TESLA-Based Defense against Pollution Attacks in P2P Systems with Network Coding (2011)

Pollution attacks are well-known to have detrimental effect on intra-session network coding in general, and in peer-to-peer (P2P) systems with network coding in particular. Previously proposed defense mechanisms against pollution attacks in intra- session network coding face various challenges that make them ill-suited for P2P systems: they are either computationally expensive, not collusion resistant, or work only on fixed, known topologies. In this work, we propose a novel, complete defense system for network coding-based P2P systems that can (i) quickly detect corrupted blocks, (ii) precisely identify the attackers, thereby eliminating them from the network, (iii) resist arbitrary collusion, and (iv) work with unknown, dynamic topologies, as it is the case in P2P systems. Our scheme uses and builds on two key ingredients: homomorphic message authentication codes and time asymmetry (as in TESLA) to provide source authentication for the detection scheme and non-repudiation for the identification scheme. Our mechanisms introduce significantly less communication and computation overhead than other comparable state-of-the-art schemes for P2P systems. Using implementation in both C/C++ and Java, on both a PC and an Android device, we show that the computational delay per block at each peer is as low as 600 microseconds and the bandwidth overhead is as low as 1.3%.
VCSELs for high power applications (2016)

High power VCSEL systems are a novel laser source, offering a unique combination of efficiency, compactness and robustness. A wide scalability of these systems in power makes them attractive for applications in industrial manufacturing. Basic properties and a first application of high power VCSEL systems are presented here.
Histograms of Motion Gradients for real-time video classification (2016)

Besides appearance information, the video contains temporal evolution, which represents an important and useful source of information about its content. Many video representation approaches are based on the motion information within the video. The common approach to extract the motion information is to compute the optical flow from the vertical and the horizontal temporal evolution of two consecutive frames. However, the computation of optical flow is very demanding in terms of computational cost, in many cases being the most significant processing step within the overall pipeline of the target video analysis application. In this work we propose a very efficient approach to capture the motion information within the video. Our method is based on a simple temporal and spatial derivation, which captures the changes between two consecutive frames. The proposed descriptor, Histograms of Motion Gradients (HMG), is validated on the UCF50 human action recognition dataset. Our HMG pipeline with several additional speed-ups is able to achieve real-time video processing and outperforms several well-known descriptors including descriptors based on the costly optical flow.
Effect of a hyperbolic metamaterial on radiation patterns of a single-photon source (2015)

We explore the effect of a planar hyperbolic metamaterial (a superlattice of TiN and Al0.7Sc0.3N on MgO substrate) on the far-field radiation patterns of a single-photon source (a nitrogen-vacancy center in a nanodiamond).
IMAGE TRANSMISSION WITH ADAPTIVE POWER AND RATE ALLOCATION OVER FLAT FADING CHANNELS USING JOINT SOURCE CHANNEL CODING (2006)

A joint source channel coder (JSCC) for image transmission over flat fading channels is presented. By letting the transmitter have information about the channel, and by letting the code-rate vary slightly around a target code-rate, it is shown how a robust image coder is obtained by using time discrete amplitude continuous symbols generated through the use of nonlinear dimension changing mappings. Due to their robustness these mappings are well suited for the changing conditions on a fading channel.